Key result
Rivaroxaban monotherapy successfully treats recurrent VTE in cases of hereditary protein S deficiency.
Why the study?
It is unknown whether rivaroxaban is effective for treating VTE in patients with thrombophilia, including hereditary protein S deficiency, due to a lack of evidence.
Does rivaroxaban monotherapy successfully treat recurrent VTE in patients with hereditary protein S deficiency?
Does rivaroxaban monotherapy successfully treat recurrent VTE in patients with hereditary protein S deficiency?
Rivaroxaban monotherapy may be an effective treatment option for recurrent VTE in patients with hereditary protein S deficiency, a population where its efficacy was previously unknown.
Rivaroxaban may warrant consideration in protein S deficiency VTE; hypothesis-generating and requires prospective validation before practice change.
Hereditary protein S deficiency is an autosomal dominant disorder associated with a high risk of venous thromboembolism (VTE) and usually results from mutations of PROS1 . Historically heparin and warfarin have been applied as recommended treatment of VTE. Recent researches showed that rivaroxaban provided more consistent and predictable anticoagulation than warfarin. However, it is unknown whether rivaroxaban is effective for the treatment of VTE in patients with thrombophilia, including protein S deficiency, due to lack of evidence. Here, we report two cases of recurrent VTE in two patients with hereditary protein S deficiency, owing to the same nonsense mutation in PROS1 , which were successfully treated by rivaroxaban monotherapy.
No takes yet. Share an insight, caveat, or question.
Lou et al. (2020) studied this question. Rivaroxaban monotherapy successfully treated recurrent venous thromboembolism in two patients with hereditary protein S deficiency caused by a PROS1 mutation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: